Blog - Techseriesinsight

November 8, 2024
PRNewswire
Biotechnology

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced the...

November 8, 2024
PRNewswire
Networking

ZTE hosts 5G Summit & User Congress 2024 in Türkiye, showcasing the digital future under the theme “Flourish Through Intelligent Innovation”

ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology solutions, has hosted its annual 5G Summit & User Congress 2024 in Istanbul, Türkiye. The...

November 8, 2024
Business Wire
Analytics

Confluence’s Revolution solution recognized as Best Buy-side Risk Management Initiative by Waters Technology

Confluence Technologies, Inc. (“Confluence”), a global technology solutions provider for regulatory, analytics, and investor communications solutions for the investment management industry, proudly announced that its Revolution solution for multi-asset performance,...

November 8, 2024
PRNewswire
Customer Experience

Nansha Shines at CIIE: Converging at the Bay, Connecting to the World

This is a news release from Nansha Economic and Technological Development Zone Commerce Bureau, Guangzhou: From November 5 to 10, 2024, the 7th China International Import Expo (CIIE) is being...

November 8, 2024
PRNewswire
Healthcare

Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today the submission of a New Drug Application (NDA) to the...

November 8, 2024
PRNewswire
Biotechnology

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor...

November 8, 2024
PRNewswire
Networking

ITRI Joins Forces with EU 6G-SANDBOX for Advanced 6G R&D

At the 2024 EU-TW 6G SNS Joint Workshop in Taipei, the Industrial Technology Research Institute (ITRI), alongside its Taiwanese partners and the EU 6G-SANDBOX, presented the outcomes of their collaboration, showcasing...

November 7, 2024
tsi_admin
Insights

The Digital Lending Revolution: A New Era of Financial Accessibility

Digital lending platforms are revolutionizing the financial landscape, reshaping the way community banks, credit unions, and traditional lending institutions operate. Leveraging advanced technologies like artificial intelligence (AI), these platforms...

November 7, 2024
Business Wire
Biotechnology

Murata’s Revolutionary Stretchable Printed Circuit Elevates Wearable Medical Devices

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) reveals an innovative new Stretchable Printed Circuit (SPC) technology marking a significant development in printed circuit technology. Murata’s SPC represents the...

November 7, 2024
Business Wire
Biotechnology

MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through...